An alliance for the enablement of
small-molecule R&D, spanning from Hit finding up to the
preparation of the Investigational New Drug filing
Regulatory News:
ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC) and HITGEN
(688222.SH) today announced the start of a worldwide strategic
alliance in Integrated Drug Discovery Services for the
identification and progression of new chemical entities, spanning
from Hit finding up to preparation of the Investigational New Drug
filing.
Facilitating this joint integrated drug discovery service,
HitGen will apply its powerful DNA Encoded Library (DEL) technology
platform and its large collection of novel, diverse and drug-like
DELs. This technology has gained widespread interest in the
pharmaceutical and biotech sectors in recent years, driven by
broad-based success in identifying novel, tractable small-molecule
ligands for novel therapeutic targets.
Oncodesign will carry on the innovation process through its
DRIVE-for small molecules discovery new services offer capitalizing
on its innovative technology and solid experience in drug discovery
and extensive disease biology expertise in Oncology and
Inflammatory diseases to design and deliver leads and preclinical
candidates of high quality for progressing them up to the IND
submission.
Through this strategic partnership in Integrated Drug Discovery
Services, Oncodesign strengthens the fully integrated drug
discovery support required to develop programs from target
identification through to IND submission. These joint capabilities
enable clients in the pharma industry to leverage the benefits of
HitGen’s DEL technology platform with Oncodesign’s drug development
expertise in major therapeutic areas with the aim to discover and
progress new drug candidates towards a clinical
proof-of-concept.
Fabrice Viviani, Senior Executive Vice-President and Chief of
Oncodesign Services said: "We are extremely delighted to engage
with HitGen, a highly recognized and world leader in DNA-encoded
libraries, into this strategic partnership. We are excited to join
our forces and complementary expertise within the DRIVE-for small
molecules offer to further gain recognition of our ability to
identify and generate together novel pre-clinical candidates ready
to progress into the clinic."
Philippe Genne, Chairman, Chief Executive Officer and Founder
of Oncodesign added: “Through this partnership, we are building
an innovative technological continuum aiming to provide clients
with a complete service offer in the development of drug
candidates. Perfectly complementary with our expertise, HitGen's
technology is positioned upstream on the value chain of Drug
Discovery process and, thus, enables us now to generate hits,
compounds with desired activity related to the new therapeutic
targets. This alliance will support our expansion on the IDDS
market, which until now has been reserved for larger Contract
Research Organizations (CRO). This agreement gives us an
international positioning, including Asia, the US and Europe. The
co-branding around the DRIVE -SM offer will be an efficient
leverage to generate commercial synergies. The marketing of the
IDDS offer is a strategic element for the growth of our service
revenue and the achievement of our 2023 objectives.”
Jin Lin, Chairman and Chief Executive Officer of HitGen
added: “We are delighted to enter this collaboration with
Oncodesign. We believe the collaboration will reinforce the role
and reputation of HitGen’s platform in the rapidly developing field
of DNA-encoded libraries (DELs) and further accelerate the
effective translation from DEL hits to clinical candidates for a
variety of therapeutic targets.”
About HitGen Inc.: www.hitgen.com
HitGen is a rapidly growing biotech company with headquarters
based in Chengdu, China, with a subsidiary in the USA. HitGen has
established an industry-leading platform for early-stage drug
discovery research centered on DNA encoded chemical libraries
(DELs). HitGen’s DELs include encoded syntheses for hundreds of
billions of novel, diverse, drug-like small molecule and macrocycle
compounds. These compounds are members of DELs synthesized from
many hundreds of distinct chemical scaffolds, designed and
assembled with tractable chemistry based on proven results for
identifying drug-like leads against biological targets from known
and novel classes. HitGen is working with multiple pharmaceutical
and biotech companies, foundations and research institutes in North
America, Europe, Australia and Asia to discover and develop novel
therapeutics of the future.
About ONCODESIGN: www.oncodesign.com
Founded 25 years ago by Dr. Philippe Genne, the Company’s CEO
and Chairman, Oncodesign is a biopharmaceutical company dedicated
to precision medicine. With its unique experience acquired by
working with more than 800 clients, including the world’s largest
pharmaceutical companies, along with its comprehensive
technological platform combining state-of-the-art medicinal
chemistry, pharmacology, regulated bioanalysis, medical imaging and
Artificial Intelligence, Oncodesign is able to predict and
identify, at a very early stage, each molecule's therapeutic
usefulness and potential to become an effective drug. Applied to
kinase inhibitors, which represent a market estimated at over $65
billion by 2027 and accounting for almost 25% of the pharmaceutical
industry’s R&D expenditure, Oncodesign’s technology has already
enabled the targeting of several promising molecules with
substantial therapeutic potential, in oncology and elsewhere, along
with partnerships with pharmaceutical groups such as Bristol-Myers
Squibb. Oncodesign is based in Dijon, France, in the heart of the
town’s university and hospital hub, and within the Paris-Saclay
cluster. Oncodesign has 233 employees and subsidiaries in Canada
and the USA.
Disclaimer
This press release contains certain forward - looking statements
and estimates concerning the Company’s financial condition,
operating results, strategy, projects and future performance and
the markets in which it operates. Such forward-looking statements
and estimates may be identified by words such as “anticipate,”
“believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is
designed to,” “may,” “might,” “plan,” “potential,” “predict,”
“objective,” “should,” or the negative of these and similar
expressions. They incorporate all topics that are not historical
facts. Forward looking statements, forecasts and estimates are
based on management’s current assumptions and assessment of risks,
uncertainties and other factors, known and unknown, which were
deemed to be reasonable at the time they were made but which may
turn out to be incorrect. Events and outcomes are difficult to
predict and depend on factors beyond the Company’s control.
Consequently, the actual results, financial condition, performances
and/or achievements of the Company or of the industry may turn out
to differ materially from the future results, performances or
achievements expressed or implied by these statements, forecasts
and estimates. Owing to these uncertainties, no representation is
made as to the correctness or fairness of these forward-looking
statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates speak only as of the date on
which they are made, and the Company undertakes no obligation to
update or revise any of them, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200525005206/en/
HitGen For more information, please call
+86-28-85197385, +1 508-840-9646 or visit www.hitgen.com.
For media inquiries: media@hitgen.com For investor
inquiries: investors@hitgen.com For business development:
bd@hitgen.com
Oncodesign Philippe Genne Chairman and CEO Tel. : +33
(0)3 80 78 82 60 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Louis-Victor
Delouvrier Tel. : +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel. : +33 (0)1 44
71 00 15 oncodesign@newcap.eu